Abstract: Polymer conjugates are provided that are capable of mimicking functions of natural proteoglycans found in the extracellular matrix of connective tissues. The polymer conjugates of the invention have utility in treating a subject suffering soft tissue conditions. Also provided are simple and scalable chemical processes for the preparation of the polymer conjugates of the invention.

Abstract: A preparation method of sodium hyaluronate with a full molecular weight distribution (MWD) is provided, including: step 1): spraying hydrogen peroxide on a sodium hyaluronate solid raw material, and conducting an ultraviolet (UV) irradiation treatment; step 2): dissolving a sodium hyaluronate degradation material in water, and adjusting a pH to higher than 7.0; step 3): subjecting a sodium hyaluronate alkaline solution to an ultrasonic treatment; step 4): preparing the sodium hyaluronate solid raw material into a sodium hyaluronate solution with a concentration of 0.1% to 1% (w/v), and thoroughly mixing the sodium hyaluronate solution in an addition proportion of 20% to 60% (v/v) with the sodium hyaluronate alkaline solution obtained after the ultrasonic treatment; and step 5): subjecting a resulting mixed solution to an adsorption treatment with diatomaceous earth and activated carbon, filtering for concentration, and drying a resulting concentrate to obtain the sodium hyaluronate with a full MWD.

Abstract: A pharmaceutical composition for treating an ischemic tissue, comprising: a core component and a matrix component, wherein the core component includes a heparin or derivative thereof and the matrix component includes a hyaluronan or derivative thereof, the pharmaceutical composition having a viscosity greater than 10 mPa-s.

Abstract: Compositions comprising mixtures of hydroxypropyl-?-cyclodextrin, wherein the compositions may be isomerically purified, and methods of isomerically purifying a mixture of hydroxypropyl-?-cyclodextrins.

Abstract: Low endotoxin fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising less than about 0.2, 0.18, 0.1, 0.01, 0.001, or 0.0005 endotoxin units (EU) per milligram of the fucan are disclosed. Methods and systems for removing or reducing the amount of endotoxins from a starting fucan composition are also disclosed.

Abstract: The invention discloses a biological desulfurizer for removing organic sulfur in fracturing flowback fluid and application thereof. The biological desulfurizer includes a compound with a triazine structure formed by modifying chitosan with aldehydes and inorganic salts. The triazine structure has a good removal effect on hydrogen sulfide and organic sulfur such as mercaptan and sulfide. The biological desulfurizer of the invention has a sulfur capacity of up to 250 g/kg and a desulfurization efficiency of over 95% in 15 min. It can effectively remove the stink of sulfur-containing working water, improve the working environment of the well site, and reduce the impact of sulfur compounds on the atmospheric environment during the development of oil and gas fields.

Abstract: The invention relates to a method for treating a nanofibrillar cellulose hydrogel, wherein the method comprises the steps of: providing a nanofibrillar cellulose hydrogel, wherein the nanofibrillar cellulose is oxidized nanofibrillar cellulose, wherein the oxidation has been carried out through N-oxyl mediated catalytic oxidation of cellulose-based raw material, and has at most 50 ?mol of aldehyde groups per gram of dry nanofibrillar cellulose; and subjecting the nanofibrillar cellulose hydrogel to a heat treatment.

Abstract: Polymer conjugates are provided that are capable of mimicking functions of natural proteoglycans found in the extracellular matrix of connective tissues. The polymer conjugates of the invention have utility in treating a subject suffering soft tissue degenerative conditions. Also provided are simple and scalable chemical processes for the preparation of the polymer conjugates of the invention.

Abstract: The present invention relates to a compound comprising a modified saccharide moiety conjugated to a nucleic acid. The compound is useful in medicine for RNA interference therapy or for research and diagnostic purposes. In particular, the compound is useful in treating liver disease.

Abstract: Nanocellulose containing a sulfuric acid group and/or a sulfo group, each of which is derived from a sulfuric acid treatment, and an anionic functional group derived from a hydrophilization treatment. The total amount of the sulfuric acid group and/or the sulfo group and the anionic functional group is more than 0.1 mmol/g and not more than 4.0 mmol/g. Also disclosed is a product including a mixture containing the nanocellulose and a method for producing the nanocellulose.

Abstract: The present invention provides a process for producing a nanocellulose material, comprising: fractionating a lignocellulosic biomass feedstock in the presence of a solvent for lignin and water, but no acid catalyst, to generate cellulose-rich solids; and then mechanically treating the cellulose-rich solids to form a nanocellulose material comprising cellulose nanofibrils and/or cellulose nanocrystals. Many organic or inorganic solvents are possible. In some embodiments, the solvent for lignin is an oxygenated organic compound, such as a C1-C18 alcohol, e.g. ethanol, ethylene glycol, propanol, propanediol, glycerol, butanol, or butanediol. The solvent for lignin may be an aromatic alcohol, such as phenol, cresol, or benzyl alcohol. The solvent for lignin may be a ketone, an aldehyde, or an ether, such as methyl ethyl ketone or diethyl ether. The solvent for lignin may be a non-oxygenated alkane, olefin, or aromatic hydrocarbon. In some embodiments, the solvent for lignin is an ionic liquid.

Abstract: The present invention relates to a carboxyalkyl chitosan having a zeta potential, measured at pH 7.5, that is less than or equal to ?20 mV, compositions comprising same, a process for manufacturing same, and various applications thereof, in particular in the field of therapy, rheumatology, ophthalmology, esthetic medicine, plastic surgery, internal surgery, dermatology or cosmetics.

Abstract: The application of a highly controlled, micron-sized, branched, porous architecture to enhance the handling properties and degradation rate of hydrogels is described in the instant invention. A previously described pattern created through one-step nucleated crystallization in a hydrogel film creates tunable mechanical properties and/or chemical stability for use in tissue engineering applications. The bulk mechanical properties and the degradation rate of the material can be tuned easily by the addition or subtraction of crystalline structure or by the addition and subtraction of backfill material, making this useful for a variety of applications. Relevant mechanical properties that can be tuned through the application of this unique porosity are moduli, elasticity, tensile strength, and compression strength. The method of the present invention can be applied to biopolymers and natural materials as well as synthetic materials.

Abstract: A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, diallyl disulfide, allicin, sugammadex, sulfanilamide, disulfiram, sulfonamide, sulfonates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.

Abstract: [Object] An object is to provide a sulfonated fine cellulose fiber having excellent transparency, a sulfonated pulp fiber suitable for the sulfonated fine cellulose fiber, a method for producing these fibers, and a derivative pulp containing the sulfonated pulp fiber. [Means for achieving the object] The sulfonated pulp fiber of the present invention is a pulp fiber comprising a plurality of cellulose fibers, wherein a part of hydroxyl groups of the cellulose fibers of the pulp fiber is substituted with sulfo groups, an introduction amount of sulfur attributable to the sulfo groups is adjusted to be higher than 0.42 mmol/g while maintaining a fiber shape, and a water retention value of the pulp fiber is adjusted to 150% or more. Since the sulfonated pulp fiber has a predetermined water retaining property or more while maintaining the fiber shape, the degree of flexibility in handling can be improved.

Abstract: Disclosed are ophthalmic formulations which use complexes called L/H-HA, obtainable by subjecting at least two fractions of hyaluronic acids and/or other glycosaminoglycans with different molecular weights to an appropriate heat cycle.

Abstract: The invention includes chitosan nanofibers having enhanced structural integrity, compositions comprising such chitosan nanofibers, and related methods of use. In a particular aspect, electrospun chitosan nanofibers can be reversibly acylated to enhance structural integrity and promote healing and the formation of tissues in a subject. In another aspect, electrospun chitosan nanofibers comprising at least a portion of the amino groups protected, such as through N-tert-butoxycarbonyl groups, demonstrate enhanced structural integrity and promote healing and the formation of tissues in a subject. The invention also includes compositions and methods for producing a modified chitosan material having anti-inflammatory and pro-healing characteristics and methods of using the modified chitosan materials in a film, a gel, a membrane, microfibers, nanofibers, nano- or micro-particles/spheres and/or sponges. In some aspects, microspheres and methods of producing microspheres comprising modified chitosan are included.

Abstract: A process for dissolving modified cellulose is disclosed. The process includes contacting modified cellulose with a solvent in a mixture to form swelled modified cellulose and then contacting the mixture with a salt to dissolve the swelled modified cellulose.

Abstract: There is provided a method for producing hydroxypropyl methyl cellulose phthalate (HPMCP), including an esterification step of reacting hydroxypropyl methyl cellulose with a carboxybenzoylating agent in the presence of an aliphatic carboxylic acid in a kneader reactor equipped with two or more stirring blades rotating around their own axes and orbitally revolving, to obtain a reaction product solution containing HPMCP; a precipitation step of precipitating the HPMCP by mixing the reaction product solution with water to obtain a suspension of the precipitated HPMCP; and a washing and recovery step of washing the HPMCP in the suspension and recovering the washed HPMCP. Further, there is provided HPMCP having yellowness at 20° C. of 10.0 or less, as determined in a 10% by mass solution of the HPMCP in acetone.

Abstract: The present disclosure relates to compounds and methods of eradicating cancer stem cells by combining inhibitors of oxidative metabolism and glycolytic metabolism. Also described are compounds and methods of identifying a combination of inhibitors of oxidative metabolism and glycolytic metabolism to treat cancer stem cells.